Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
NCT02709889
Terminated
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/21/2020
Locations: Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert, Arizona +29 locations
Conditions: Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Large-Cell Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Register for Updates
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
NCT01104025
Completed
Despite good progress during the last decade, hemophagocytic lymphohistiocytosis (HLH) remains difficult to treat. Two different treatment regimens have been used successfully. The first one, a treatment regimen based on two drugs called etoposide and dexamethasone, has been used worldwide. The second regimen, based on two drugs called Anti-thymocyte globulin (ATG) and prednisone, has been used mostly at one hospital in Paris, for over 15 years. With either regimen, about three quarters of treat... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
09/21/2020
Locations: Phoenix Children's Hospital, Phoenix, Arizona +14 locations
Conditions: Hemophagocytic Lymphohistiocytosis
Register for Updates
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
NCT01989325
Completed
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2020
Locations: Genesis Cancer Center, Hot Springs, Arkansas +21 locations
Conditions: Advanced Multiple Myeloma
Register for Updates
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
NCT01938729
Completed
This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels. All patients will have an operation to remove tumors in the liver and may have a pump placed in their abdomen. On this study, both drugs given have been used in other patients for treatment of cholangiocarcinoma and other gastrointestinal cancers. Both drugs are approved by the food and drug administration (FDA)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2020
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
Register for Updates
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00137111
Completed
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
Gender:
ALL
Ages:
Between 12 months and 18 years
Trial Updated:
09/09/2020
Locations: St Jude Children's Research Hospital, Memphis, Tennessee +1 locations
Conditions: Lymphoblastic Leukemia, Acute
Register for Updates
Dexamethasone and Post-tonsillectomy Pain in Children
NCT02793011
Completed
The investigators will use a prospective randomized, controlled design utilizing a single preoperative dose of oral dexamethasone or placebo to achieve these specific aims: * Specific Aim 1: To evaluate the potential for a single preoperative dose of oral dexamethasone administered the night before surgery to reduce the incidence and severity of early post tonsillectomy pain (PTP) in children * Specific Aim 2: To prospectively evaluate differences in early PTP experience between overweight/obes... Read More
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
09/09/2020
Locations: University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Pediatric Post-tonsillectomy Pain
Register for Updates
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
NCT01083316
Completed
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis. We want to find out if the addition of dexamethasone and bortezomib to standard high dose chemotherapy and stem cell transplant can help improve response. Standard treatment includes four steps: 1) Stem Cell Mobilization (standard) 2) Stem Cell Collection (standard) 3) Conditionin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2020
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Amyloidosis
Register for Updates
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
NCT01570387
Completed
This study seeks to enroll patients with AL amyloidosis, for whom treatment with one of the standard melphalan chemotherapy-based regimens is either not recommended or is not their preference. Pomalidomide (CC-4047) is a drug given by mouth, which can change or regulate the functioning of the immune system. So, in theory, it may reduce or prevent the production of the amyloid protein. Pomalidomide is not currently FDA-approved for AL Amyloidosis. Pomalidomide is chemically similar to thalidomid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2020
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: AL Amyloidosis
Register for Updates
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
NCT00290433
Completed
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/02/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03515200
Terminated
Leukemia cells grow and divide fast and out of control. In normal cells, certain proteins called CDK4 and CDK6 control cell growth. The study drug called palbociclib works by blocking the CDK4 and CDK6 proteins. Palbociclib has been shown to kill leukemia cells in the laboratory and in animal studies. Palbociclib will be added to other chemotherapy drugs, such as dexamethasone, that are known to be effective in treating childhood ALL. This study will be done in two parts: Part 1: Dose Escalatio... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/28/2020
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Register for Updates
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
NCT03023878
Completed
A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/26/2020
Locations: Research Site, Chicago, Illinois +23 locations
Conditions: High-risk Diffuse Large B-Cell Lymphoma
Register for Updates
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
NCT02400437
Completed
This research study is evaluating a drug called ixazomib (also known as MLN9708) in combination with dexamethasone and rituximab (the regimen is called IDR) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2020
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Waldenstrom's Macroglobulinemia
Register for Updates